Pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Friday announced positive results from the Phase 3b ADapt study, demonstrating the efficacy of EBGLYSS in treating moderate-to-severe atopic dermatitis (eczema) patients who had previously been treated with dupilumab.
The study showed that EBGLYSS significantly improved skin clearance, reduced itch, and addressed difficult-to-treat areas like the face and hands.
These findings highlight the potential of EBGLYSS as a valuable treatment option for a broader range of atopic dermatitis patients.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA